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Clausenidin from Clausena excavata induces apoptosis in hepG2 cells via the 
mitochondrial pathway 
 
Abstract 
 
Ethnopharmacological relevance: Clausena excavata Burm.f. is used locally in folk medicine 
for the treatment of cancer in South East Asia. 
Aim of the study: To determine the mechanism of action of pure clausenidin crystals in the 
induction of hepatocellular carcinoma (hepG2) cells apoptosis. 
Materials and methods: Pure clausenidin was isolated from Clausena excavata Burm.f. and 
characterized using 
1
H and 
13
C NMR spectra. Clausenidin-induced cytotoxicity was 
determined by MTT assay. The morphology of hepG2 after treatment with clausenidin was 
determined by fluorescence and Scanning Electron Microscopy. The effect of clausenidin on 
the apoptotic genes and proteins were determined by real-time qPCR and protein array 
profiling, respectively. The involvement of the mitochondria in clausenidin-induced 
apoptosis was investigated using MMP, caspase 3 and 9 assays. 
Results: Clausenidin induced significant (p<0.05) and dose-dependent apoptosis of hepG2 
cells. Cell cycle assay showed that clausenidin induced a G2/M phase arrest, caused 
mitochondrial membrane depolarization and significantly (p<0.05) increased expression of 
caspases 3 and 9, which suggest the involvement of the mitochondria in the apoptotic signals. 
In addition, clausenidin caused decreased expression of the anti-apoptotic protein, Bcl 2 and 
increased expression of the pro-apoptotic protein, Bax. This finding was confirmed by the 
downregulation of Bcl-2 gene and upregulation of the Bax gene in the treated hepG2 cells. 
Conclusion: Clausenidin extracted from Clausena excavata Burm.f. is an anti-hepG2 cell 
compound as shown by its ability to induce apoptosis through the mitochondrial pathway of 
apoptosis. Clausenidin can potentially be developed into an anticancer compound. 
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